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60Objective: Cardiogenic shock is associated with poor clinical outcomes. Extracorporeal life support is used in
most centers for short-term circulatory support. Alternatively, the Impella LP 5.0 and right direct (RD) micro-
axial ventricular assist device (Abiomed, Danvers, Mass) can provide isolated left and right ventricular support,
respectively.
Methods: A retrospective, single center review was performed on all patients receiving circulatory assistance
with either extracorporeal life support or Impella ventricular assist device. All Impella LP 5.0 were inserted
via the femoral artery, while the RD system required sternotomy.
Results: Twenty-nine patients received ventricular assist device support (Impella LP 5.0; n ¼ 24; and Impella
RD; n ¼ 5), whereas 32 patients were placed on extracorporeal life support. The baseline characteristics of pa-
tients with cardiogenic shock, assisted by Impella or extracorporeal life support, were similar, but the etiology of
cardiogenic shock was distributed differently in the 2 groups (P ¼ .008). Forty-one percent of the Impella pa-
tients and 47% of the extracorporeal life support patients were weaned from support. The 30-day mortality
(44% in the extracorporeal life support vs 38% in the Impella group) and proportion of patients discharged
home (41% in the extracorporeal life support vs 59% in the Impella group) were not statistically different be-
tween the 2 groups. Arterial thrombosis was less frequent in the Impella group (3.4% vs 18.8%; P¼ .04). Blood
product transfusions were less frequent in the Impella group (P<.001).
Conclusions: Both extracorporeal life support and axial flow pumps provided adequate support in patients with
various etiologies of cardiogenic shock. Axial-flow pump may be an optimal type of support for patients with
univentricular failure, whereas extracorporeal life support could be reserved for patients with biventricular fail-
ure or combined respiratory and circulatory failure. (J Thorac Cardiovasc Surg 2011;142:60-5)Cardiogenic shock in the postcardiotomy setting after myo-
cardial infarction or as a manifestation of acute decompen-
sated heart failure is associated with high mortality. Low
cardiac output syndrome leads to systemic hypoperfusion,
which, if not reversed, is followed by multiple organ dys-
function syndrome and death. Treatment options available
when patients present with low cardiac output states include
revascularization, correction of surgical pathology, and me-
chanical support of the failing heart. Mechanical circulatory
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The Journal of Thoracic and Cardiovascular Surgetion (IABP), ventricular assist devices (VADs), and extra-
corporeal life support (ECLS), also called veno-arterial
extracorporeal membrane oxygenation (ECMO). Isolated
right ventricular failure is rare after cardiac surgery or myo-
cardial infarction, and it requires management with fluid
optimization, inotropes, and pulmonary vasodilators. De-
spite aggressive management, including right ventricular
support devices, its mortality ranges from 50 to 60%.1
In an effort to decrease the invasiveness of the devices
used for support, smaller temporary VADs have become
available in the form of endovascular axial flow pumps for
the right and left ventricle. The Impella recover system
(Abiomed, Danvers, Mass) includes pumps that can be in-
serted peripherally, such as the left peripheral (2.5 L or 5.0
L [LP2.5 andLP5.0]), or centrally for the left is the left direct
(LD) or for the right is the right direct (RD) ventricular sup-
port.2-4 The use of these devices has been reported by several
centers, although mostly in the form of small case series or
case reports.3-8 In the postcardiotomy setting, Impella
support has been compared, in a retrospective analysis, to
intra-aortic balloon counterpulsation.9 The use of axial-
flowpumps has also been reported in several trials as support
for high-risk percutaneous coronary interventions.10-14
However, most of these trials compare the Impella LP2.5ry c July 2011
Abbreviations and Acronyms
CPR ¼ cardiopulmonary resuscitation
ECLS ¼ extracorporeal life support
ECMO ¼ extracorporeal membrane oxygenation
eCPR ¼ mechanically assisted cardiopulmonary
resuscitation
IABP ¼ intra-aortic balloon counterpulsation
IQR ¼ interquartile range
LV ¼ left ventricular
PRBC ¼ packed red blood cells
RD ¼ right direct
RV ¼ right ventricle
VAD ¼ ventricular assist device
Lamarche et al Acquired Cardiovascular Disease
A
C
Ddevice, with a maximal output of 2.5 L/min, and IABP. We
believe that there are no reports comparing Impella 5.0 L
devices with ECLS, in the setting of cardiogenic shock as
a bridge to recovery, to a longer-term VAD, or as a bridge
to decision strategy.
The objective of this study is to compare survival,weaning,
and bridging outcomes, as well as bleeding and thromboem-
bolic complications of consecutive patients supported by the
newly introducedmicroaxial VAD systems with ECLS in pa-
tients with severe acute cardiogenic shock in a single center.PATIENTS AND METHODS
A retrospective cohort was constructed of all patients requiringmechan-
ical circulatory support in the setting of acute, refractory, cardiogenic shock
at St. Paul’s Hospital between July 2000 and September 2009. St. Paul’s
Hospital is a 500-bed quaternary care hospital affiliated with the University
of British Columbia and offers both interventional and cardiac surgical
care. Patients presenting with acute ST segment elevation myocardial in-
farctions were directed according to protocolized care to the catheterization
laboratory for percutaneous intervention with surgical backup. Patients
with postcardiotomy shock were evaluated for residual surgical defects,
and correction was performed by either a surgical or percutaneous ap-
proach. All patients having potential for recovery were considered for me-
chanical support if their systemic perfusion did not improvewith IABP and
inotropes. Potential for recovery was described as absence of irreversible
multiorgan dysfunction and was evaluated by consensus between the sur-
geons and cardiologists from the heart failure team. Etiology and severity
of shock was described by cause and by the extent of the pharmacologic
and mechanical support required, including IABP and cardiopulmonary re-
suscitation (CPR). Patients requiring cardiopulmonary resuscitation con-
tinuously, intermittently, or on very high doses of vasopressors and
inotropes (norepinephrine>20 mg/min or unstable despite three or more
vasopressors and/or inotropes) were considered as undergoing mechani-
cally assisted cardiopulmonary resuscitation (eCPR). Patients with cardio-
genic shock with echocardiographic signs of isolated right ventricular
failure (distension, left-sided displacement of interventricular septum,
and severe tricuspid regurgitation) were considered for support with
ECLS (2000–2009) or right-sided axial flow pump (Impella RD, 2007–
2009). Demographics, diagnosis, type of support, and flow data were ob-
tained from a registry containing perioperative information of all patients
requiring mechanical support. Complications and outcomes were obtained
by chart revision and institutional database for discharge status.The Journal of Thoracic and CSupport Systems
The only support system available in patients failing despite IABP ther-
apy from 2000 to 2007 was ECLS. From October 2007 to September 2009,
both ECLS and Impella systems were available.
The ECLS system was composed of Carmeda coated cannulae and cir-
cuit (Biomedicus; Medtronic, Minneapolis, Minn). Cannula size varied and
ranged from 17 to 23 French and 20 to 29 French for arterial and venous
access, respectively. The oxygenator and heat exchanger were also
heparin-coated (Quadrox D oxygenator Maquet, Hirrlingen, Germany).
A Biomedicus centrifugal pump head was used initially and was replaced
with the Rotaflow pump (Maquet) in more recent cases. Patients requiring
emergency support in the cardiac catheterization laboratory received per-
cutaneous veno-arterial cannulations. Patients in the postcardiotomy set-
ting had either central or peripheral veno-arterial cannulation. Heparin
was used during cannulation and weaning only. No left ventricular vent
was inserted in patients supported with ECLS.
The Impella Recover system is composed of an axial-flow pump driven
by an electric motor. The Impella LD and LP 5.0 system consists of a 21-
French inflow tip positioned into the left ventricle and the outflow in the
aorta. The LP system was introduced in the femoral artery after a vascular
cut down, either through a direct canulation of the artery through a purse-
string or through a vascular graft. Once the pump was positioned under
fluoroscopy into the left ventricle, the 9-French driveline was connected
to the console. Patients supported by the RD system had direct right atrial
and main pulmonary artery canulation through median sternotomy, with
purse string sutures ensuring hemostasis around the inflow and outflow
cannulae. Intravenous heparin was given at the time of pump insertion to
obtain an ACT> 300 seconds. During support, a partial prothrombin
time (PTT) of 45 to 60 seconds was maintained with continuous heparin
infusion.
Selection and Management of Devices
Between 2007 and 2009, both the Impella systems and ECLS were
available. Patients with biventricular failure and oxygenation problems
were supported by ECLS. Patients with unilateral ventricular failure
were supported with the Impella systems.
Transesophageal echocardiographyprovidedassistanceduringboth device
insertion and explantation, as well as during patient’s circulatory support as
needed. Systematic transthoracic echocardiograms were performed every 48
hours during support to assess myocardial recovery, the presence of intracar-
diac thrombus, and device placement. Thromboembolic complications were
considered when thrombotic material was identified in the arterial system,
or when a limb or an organ became clinically ischemic secondary to thrombus
formation, embolism, or suspected physical obstruction by a cannula.
Patients were assessed for recovery of organ failure and neurologic
complications. If no signs of myocardial recovery were present, patients
were considered for an implantable long-term VAD if they were transplant
candidates.
Statistical Analysis
Data is presented as median interquartile range (IQR) or mean stan-
dard deviation. Categorical data was compared with c2 analysis or Fisher
exact test where appropriate. Mann–Whitney U Test was used for continu-
ous variables. All statistical evaluations were performed using Stata version
11 (StataCorp, College Station, Tex). A statistically significant difference
was defined as a two-sided P value less than .05.
This study was approved by the clinical research ethics board at St.
Paul’s Hospital and the University of British Columbia.RESULTS
During the 9-year study period, 7952 patients had open
heart surgery at St. Paul’s Hospital. There were 142 heartardiovascular Surgery c Volume 142, Number 1 61
TABLE 1. Patient characteristics: extracorporeal life support, intra-
aortic balloon pump, ejection fraction, standard deviation, mechanically
supported resuscitation, and idiopathic dilated cardiomyopathy
ECLS
(n ¼ 32)
Impella
(n ¼ 29) P
Age (mean  SD) 50.4  14.2 53.7  13.1 .35
Male gender (%) 62.5% 82.8% .08
Diabetes (%) 20.0% 27.6% .49
Mechanically ventilated (n) (%) 32 (100) 28 (97) .29
Preoperative IABP (%) 40.6% 51.7% .39
eCPR (n) (%) 8 (25) 14 (48) .06
Mean EF (%) 20 (13–25) 20 (11–20) .54
Cause of shock .008
IDCM (%) 3.1 24.1
Ischemic (%) 40.6 37.9
Myocarditis (%) 0 10.3
Postcardiotomy (%) 43.8 13.8
Other* (%) 12.5 13.8
ECLS, Extracorporeal life support; eCPR, mechanically supported resuscitation;
EF, ejection fraction; IABP, intra-aortic balloon pump; IDCM, idiopathic dilated
cardiomyopathy; SD, standard deviation. *The category ‘‘Other’’ includes in the
extracorporeal life support (ECLS) patients: One refractory ventricular arrhythmia,
1 failing left ventricular assist device, 1 decompensated hypertrophic cardiomyopa-
thy, and 1 peripartum cardiomyopathy. In the Impella patients: 2 postcardiac trans-
plants with right ventricle failure, 1 myocarditis, and 1 refractory ventricular
arrhythmia patient.
TABLE 2. Outcomes: ventricular assist device, extracorporeal life
support, interquartile range, and standard deviation
ECLS
(n ¼ 32)
Impella
(n ¼ 29) P
Duration of support (hr)
(median  IQR)
46.3 (27–88) 63.3 (41–142) .16
Average flow (L/min)
(mean  SD)
4.0  0.1 3.7  0.1 .06
Arterial thromboembolism
(n) (%)
6 (18.8) 1 (3.4) .04
Weaned (n) (%) 15 (46.9) 12 (41.4) .67
Bridge to VAD (n) (%) 6 (18.8) 8 (27.6) .41
Bridge to transplant (n) (%) 3 (9.4) 0 .09
30-day mortality (n) (%) 14 (43.8) 11 (37.9) .64
Discharged home (n) (%) 13 (40.6) 17 (58.6) .16
ECLS, Extracorporeal life support; IQR, interquartile range; SD, standard deviation;
VAD, ventricular assist device.
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Dtransplantations and 52 implantable, long-term VADs per-
formed. During the same period, 32 patients required
ECLS. Twenty-four patients (0.3% of cases) necessitated
ECLS after cardiac surgery. Eight patients were supported
with ECLS in the setting of mechanical assistance to resus-
citation. Twenty-nine patients were supported with axial
flow pumps (Impella LP 5.0; n ¼ 24 and Impella RD;
n ¼ 5). The mean age, gender, proportion of patients with
diabetes mellitus, preoperative IABP, as well as the initial
left ventricular ejection fraction was similar between the
two groups (Table 1). There was twice as many patients re-
quiring support as a mechanical assistance to resuscitation
or as an adjunct to CPR (eCPR) in the Impella group
(P ¼ not significant). Seventy-five percent of ECLS cases
were in the postcardiotomy setting, whereas only 21% of
the Impella systems were inserted for postcardiotomy ven-
tricular failure. All patients in the ECLS group and 28
(97%) of the Impella group were mechanically ventilated
when the decision to support them was established. Patients
had an ischemic etiology in 41% and 38% of the ECLS and
Impella cases, respectively (Table 1). However, the other
etiologies of shock were different in the 2 groups
(P¼ .008), with the proportion of postcardiotomy shock be-
ing higher in the ECLS group.
Forty-seven and 41% of the ECLS and Impella patients,
respectively, were successfully weaned from mechanical
support (Table 2 and Figure 1). One patient from the Impella
group required the addition of veno-venous ECMO for hyp-
oxemic respiratory failure. Five patients had isolated right-
sided axial flow pump (Impella RD) inserted for severe right
heart failure. Four of those patients (80%) were weaned and
were subsequently discharged from the hospital. Arterial
thrombotic events were more frequent in patients receiving
ECLS (18.8% vs 3.4%; P ¼ .04). The arterial thromboem-
bolic events included 1 left ventricular thrombus and 5 epi-
sodes of leg ischemia, related to the cannulation site in the
ECLS group; in the axial flow pump group, 1 patient was di-
agnosed with heparin-induced thrombocytopenia with in-
ternal jugular vein thrombosis, mitral valve thrombosis,
and femoral artery thrombosis requiring surgery.
The 30-day mortality (44% in ECLS vs 38% in the Im-
pella group) and proportion of patients discharged home
(41% in ECLS vs 59% in the Impella group) was not statis-
tically different between the 2 groups. There were no cases
of mechanical failure requiring replacement or altered med-
ical management in the Impella group, whereas replace-
ment of circuit component was needed in 9% of ECLS
cases.
Blood products were used less frequently in the Impella
group than in the ECLS group (P<.001). The patients sup-
ported after cardiotomy required more packed red blood
cells (PRBC) transfusions than patients supported in all
other categories (18 U [IQR, 10–34) vs 4 U [IQR, 2–9];
P< .0001). Use of activated recombinant factor VII was62 The Journal of Thoracic and Cardiovascular Surgenot statistically different between groups (21.8% in ECLS
group vs 13.8% in the Impella group; P ¼ .51) (Table 3).DISCUSSION
The main findings of this analysis comparing ECLS and
axial-flow pump for circulatory support in patients with
acute cardiogenic shock are a decreased use of allogenic
blood product transfusions and fewer thromboembolic
complications in the axial-flow pump group. There was
no difference in 30-day mortality. Finally, although not sta-
tistically significant, 50% more patients in the Impellary c July 2011
FIGURE 1. Flow diagram. ECLS, Extracorporeal life support; ECMO, extracorporeal membrane oxygenation; LP, left peripheral; RD, right direct;
VAD, ventricular assist device.
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Dgroup than the ECLS group were able to be discharged
home.
The two groups of patients described in this study had
profound cardiogenic shock that was refractory to IABP
and inotropes, and all except 1 patient were mechanically
ventilated. They were supported by two devices with differ-
ent physiological effects, and the overall 30-daymortality of
44% and 38%was lower than previously reported in this pa-
tient population.9,10,15 Smedira and colleagues16 reported
a 30-day mortality of 62% in cardiogenic shock patients
supported with ECLS. Siegenthaler and colleagues9 ob-
served 54% mortality in patients with postcardiotomy low
cardiac output syndrome. Jaski and colleagues17 reported
a survival of 26% in patients supported by ECLS for shock
or cardiac arrest. The cohort presented in this study is com-
posed of patients that had markers of shock that were more
profound than patients from other recent series. In their
meta-analysis, comparing IABP and percutaneous devices
for cardiogenic shock, Cheng and colleagues10 described
patients that were not all ventilated or on vasopressors,
with mean left ventricular ejection fractions between 19%
to 31%.18-20 Despite being less supported and having
better left ventricular (LV) function, 45% and 43% of
the patients supported by VADs or IABP did not survive
30 days.
Patients described in the present study were in severe car-
diogenic shock, refractory to IABP and vasopressor sup-TABLE 3. Blood product use: Extracorporeal life support, packed red
blood cells, and fresh frozen plasma
ECLS
(n ¼ 32)
Impella
(n ¼ 29) P
PRBC (median [IQR]) 18.0 (9–34) 4 (2–9) < .001
FFP (median [IQR]) 14 (8–28) 2 (0–8) < .001
Platelets (median [IQR]) 5 (0.5–8.5) 0 (0–2) < .001
Factor VIIa (%) 21.8 13.8 .51
ECLS, Extracorporeal life support; FFP, fresh frozen plasma; PRBC, packed red
blood cells.
The Journal of Thoracic and Cport, and a significant proportion of patients required CPR
before initiation of support. Those patients required exten-
sive hemodynamic support using Impella 5.0 L or complete
cardiopulmonary bypass with ECLS as opposed to partial
support, such as Tandem Heart or Impella 2.5 L, which is
reported in most series.
Support with ECLS has been used for more than 20 years
in the postcardiotomy setting21 and more recently as a ad-
junct to CPR.22 The physiologic effects of ECLS include
unloading of the right ventricle, gas exchange, and systemic
perfusion. The left ventricle is only partially unloaded while
on ECLS, and LV afterload may be high. Left ventricular
venting and IABP have been suggested as being options
to optimize LV preload and afterload in case of LV disten-
sion with mixed results.22,23 In this series, both patients
supported by Impella and ECLS had a similar proportion
supported by IABP preoperatively, but all IABPs were
removed once the mechanical support was instituted.
Support with left-sided axial flow pump has the potential
advantages of providing systemic perfusion while ade-
quately decompressing the left ventricle and augmenting
coronary perfusion.24 The flow with both left- and right-
sided axial flow pumps is nonpulsatile. Both systems have
the potential for peripheral insertion, but the obstruction
to blood flow to the lower limb is less with the Impella sys-
tem (9 French vs 17–23 French).
Patients receiving support with the axial flow pump
required fewer transfusions, despite the requirement of sys-
temic heparin. This may be explained by fewer postcardiot-
omy patients in the Impella group. However, this may also
be a consequence of the minimal surgical access through
femoral cut down and a reduced activation of inflammatory
and coagulation cascades. The reduction of bleeding led the
clinical team to be more comfortable with therapeutic anti-
coagulation. This could explain the significant decrease in
peripheral thromboembolism in that group. The short sup-
port time on ECLS and the 44% surgical re-exploration
for bleeding or tamponade explains our strategy of avoidingardiovascular Surgery c Volume 142, Number 1 63
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Danticoagulation in that group. Despite this strategy, we ob-
served only one case of left-sided intracardiac thrombosis
as compared with Muehrcke and colleagues25 who reported
as much as 20% intracardiac thrombosis when anticoagula-
tion was avoided during ECLS. The potential limitation of
the peripheral ischemic episodes by addition of systemic an-
ticoagulation remains speculative. Seyfarth and colleagues19
also reported the absence of thromboembolic complications
in their Impella group, although they also reported increased
bleeding compared to IABP. Significant bleeding was also
reported in 52% of the surgical patients byGranfeldt and col-
leagues5 in their retrospective analysis of 50 patientswith Im-
pella support; however, most of their patients required central
cannulation with the Impella LD system. We also observed
decreased bleeding in patients whowere not in a postcardiot-
omy setting; this finding may be a confounder explaining
some of the differences in PRBC transfusions between the
ECLS and Impella groups in this cohort of patients. Pages
and colleagues26 also reported transfusion requirements
when comparing ECLS and biventricular VAD support for
cardiogenic shock. Interestingly, they observed a mean
PRBC transfusion rate of 22 and 7 in the biventricular
VAD and ECLS groups, respectively. In that series, none of
the ECLS patients were in a postcardiotomy setting or re-
quired central canulation, which was also identified as
a risk factor for transfusion in the present series. The median
duration of support with ECLS or axial flow pumps is widely
variable. Granfeldt and colleagues5 had a mean support time
of 7.3 days and 30-day mortality in the postcardiotomy co-
hort of 45%. Siegenthaler and colleagues9 supported patients
for an average of 61 hours and had a mortality of 54%. In the
patient supported by Impella reported in the present study, the
median support of less than 3 days may imply that many pa-
tient had signs of recovery relatively early after restoration of
organ perfusion. Siegenthaler and colleagues9 also suggested
a low risk of mortality (10%) for patients with residual car-
diac function as opposed to poor outcomes (88% mortality)
in patients with residual cardiac output of less than 1 L/min.9
In the present study, 47% and 41% of patients were weaned
from support in the ECLS and Impella groups, respectively.
The weaning was guided by echocardiographic signs of ven-
tricular recovery, which was believed to be a better indicator
of cardiac function than thermodilution measured cardiac
output in patients with various degrees of right ventricle
(RV) dysfunction and tricuspid regurgitation.
The 30-day survival patients supported for isolated RV
failure in the Impella group was 75% in contrast with the
results of Granfeldt and colleagues5 who observed 75%
mortality in 8 patients supported with this system and
with mortality of 57% reported by Moazami and col-
leagues1 in 30 postcardiotomy patients requiring mechani-
cal support. However, the presence of only 5 patients in
the isolated RV failure subgroup of the present study, with
some being supported in the postcardiotomy setting, after64 The Journal of Thoracic and Cardiovascular Surgemyocardial infarction or after transplant, make the compar-
ison difficult with those other 2 small cohorts.
Following its introduction in 2007, Impella rapidly be-
came the dominant mechanism of hemodynamic support at
our institution. This is evident as during the timewhere these
2 technologies were concurrently available, ECLS was used
in 5 patients compared with 29 patients in whom the Impella
was inserted. It is likely that both changes in practice and po-
tential benefits of Impella lead to a broadening of the poten-
tial indications for hemodynamic support. This is suggested
by an increase in mechanical support for cardiomyopathy
during this time. In addition, having a postcardiotomy me-
chanical backup also permits postoperative mechanical sup-
port, and facilitates the surgical treatment of higher risk
cases. Finally, good initial results with the Impella likely
lowered the threshold for univentricular mechanical support.
This retrospective series, to our knowledge, is the largest
comparative series of patients requiring full support withme-
chanical devices including axial flow pumps. In comparison
to ECLS, we have observed that the Impella device may re-
duce patient morbidity with less systemic embolism and
transfusion requirement. A nonstatistically significant trend
toward improvement in successful hospital discharge was
also noted. From a resource utilization perspective, the man-
agement of patients with the microaxial VADs did not need
24-hour onsite coveragewith perfusionists, which was neces-
sary with ECLS. The ability of the Impella system to relieve
ventricular distension is a potential advantage over other
modes of support, and it also provides support that is targeted
to the failing ventricle and optimizes coronary perfusion.
There are several limitations to this study that need to be
addressed. Confounding by indication remains a significant
source of bias in the present study as selection for whichmo-
dality of circulatory support was not random and was based
on various patient characteristics. It would be very difficult
to adjust for all of these factors, particularly given the small
numbers of this study. However, patients in both groups
were relatively similar as both had profound cardiogenic
shock that was refractory to IABP and inotropes, and all ex-
cept 1 patient were mechanically ventilated. The increasing
numbers of patients surviving the acute decompensation
event and becoming transplant or long-term VAD recipients
led to an increasing awareness of the heart failure program
from the referring physicians. The earlier referral pattern
may have led to earlier implantation of support devices later
in the series. Finally, as with all observational research, and
selection bias, unmeasured and residual confounding re-
mains an alternate explanation for our results.
CONCLUSIONS
Despite early revascularization, correction of mechanical
problems, use of IABP, and inotropes, the mortality of
patients with cardiogenic shock remains high. Aggressive
circulatory support of high-risk patients with ECLS orry c July 2011
Lamarche et al Acquired Cardiovascular Diseaseaxial-flow pumps is feasible and was associated with ac-
ceptable results. The ease of use, minimal transfusion re-
quirements and low incidence of arterial thrombosis
observed with axial flow pumps were identified as advan-
tages for the use of this technology in patients with univen-
tricular failure. The ECLS remains the short-term support of
choice in patients with shock from biventricular failure and
respiratory insufficiency.
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